Showing 1-10 of 369 results for "".
- Melodie S. Young, A/GNP-Chttps://practicaldermatology.com/profiles/melodie-s-young-agnp-c/jJq5rP/
Financial Focus for Young Physicians
https://practicaldermatology.com/topics/practice-management/financial-focus-for-young-physicians-first-build-your-foundation/21416/Two important steps young dermatologists should take now for future financial security.- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the development or exacerbation of acne …
- Dr. David Simon Wins Pershing Square Sohn Prize for Young Investigators in Cancer Research to Study Melanomahttps://practicaldermatology.com/news/dr-david-simon-wins-pershing-square-sohn-prize-for-young-investigators-in-cancer-research-to-studying-melanoma/2461722/Dr. David Simon has won the Pershing Square Sohn Prize for Young Investigators in Cancer Research to study melanoma. Dr. Simon is the Fernholz Foundation Research Scholar in Neuroscience and an assistant professor of biochemistry at Weill Cornell Medicine in New York City. The prize, now in its 1…
- Murad, Active Minds Join Forces to Help Young Adults Stress Lesshttps://practicaldermatology.com/news/murad-active-minds-join-forces-to-help-young-adults-stress-less/2461543/Murad is partnering with Active Minds, a nonprofit supporting mental health awareness and education for young adults. In 2003, Dr. Murad coined the term 'cultural stress', the day-to-day stress of modern living as a major factor contributing to the chronic exhaustion and declining health of peop…
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades. Holly and Amanda were selected by an indepen…
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review by Petra Zimmermann, …
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s Dupixent® (dupilumab) in pediatric patients as young as six months old will be presented for the first time this weekend at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference. Amy S. Paller, MD presents results of a t…
- Study: Dupixent Improves AD Symptoms in Kids As Young As Six Monthshttps://practicaldermatology.com/news/study-dupixent-improves-ad-symptoms-in-kids-as-young-as-six-months/2460898/Dupixent (dupilumab) significantly reduces signs and symptoms of moderate-to-severe atopic dermatitis in children as young as six months, a new study shows. The trial met its primary and all secondary endpoints, showing that Dupixent added to standard-of-care topical corticosteroids (TCS) signific…
- Natroba Now Approved for Scabies in Adults and Children as Young as Fourhttps://practicaldermatology.com/news/natroba-now-approved-for-scabies-in-adults-and-children-as-young-as-four/2460789/Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical tre…
- Prev
- Next